UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051909
Receipt number R000059207
Scientific Title Verification study on the effect of the test foods on improvement quality of sleep
Date of disclosure of the study information 2023/08/15
Last modified on 2023/10/30 18:38:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification study on the effect of the test foods on improvement quality of sleep

Acronym

Verification study on the effect of the test foods on improvement quality of sleep

Scientific Title

Verification study on the effect of the test foods on improvement quality of sleep

Scientific Title:Acronym

Verification study on the effect of the test foods on improvement quality of sleep

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this 8-weeks study is to verify the effect of the test foods on improvement quality of sleep in Japanese healthy male/female adults, who are not satisfied with their quality of sleep.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

OSA sleep inventory MA version (OSA-MA),
Visual analogue scale for sleep

Key secondary outcomes

OSA-MA (initiation and maintenance of sleep, frequent dreaming, refreshing, sleep length), AIS, JESS, Electroencephalogram (initiation of sleep, nocturnal awakening, sleep efficiency, REM/non-REM sleep), Fitbit Versa 3 ( snore, noise level, sleep score), The proportion of division and family of intestinal bacteria


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily intake of test food for 8 weeks

Interventions/Control_2

Daily intake of placebo (control food) for 8 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Healthy Japanese male/female who are 20 years of age or older at the time of consent.
(2)Subjects who are not satisfied with their sleep quality.
(3)Those who are able to keep their bed room at their comfortable temperature.
(4)Those who have signed a consent form prior to the start of the study upon full explanation of the purpose and content of the study.

Key exclusion criteria

(1)Those who are on treatment for a serious illness.
(2)Those who are at late night work, shift work, or heavy work.
(3)Those whose sleep time or sleep habits are irregular on weekdays.
(4)Those who visit the hospital because of mental disorders (depression etc.) or sleep disorders, or who have been diagnosed with mental disorders.
(5)Those who have been diagnosed as Sleep Apnea Syndrome or have subjective symptoms of apnea.
(6)Those who select "I would like to kill myself." or "I would kill myself if I had the chance." at question 9 of Beck Depression Inventory-II (BDI2) at the screening test.
(7)Those who are habitual smokers.
(8)Those who are in the habit of consuming foods that inhibit sleepiness before bedtime or using devices that inhibit sleepiness.
(9)Those who with metal Allergies or sensitive skin.
(10)Those who may be prevented from sleep by others, including preschoolers, care required, one(s) who share bedroom.
(11)Those with food allergies or those who may be allergic to the test food.
(12)Those who regularly use licensed drugs or quasi-drugs that may affect the study.
(13)Those who regularly use health foods that may affect the study.
(14)Those who are participating in a clinical trial or have participated in another clinical trial within 1 months from the date of obtaining consent.
(15)Those who may be unable to maintain their daily lifestyle.
(16)Those who are pregnant or breastfeeding or planning to become pregnant during the study.
(17)Those who plan to participate in any other clinical trial during the study.
(18)Those who are deemed inappropriate for this study by the investigator.

Target sample size

102


Research contact person

Name of lead principal investigator

1st name Shuichi
Middle name
Last name Segawa

Organization

Nissin York Co., Ltd.

Division name

Development Laboratories

Zip code

348-8549

Address

272, Tsutsumine, Kamimurakimi, Hanyu-shi, Saitama, Japan

TEL

048-565-4686

Email

shuichi.segawa@nissin.com


Public contact

Name of contact person

1st name Yuki
Middle name
Last name Kitahara

Organization

Apoplis Station Co.,Ltd.

Division name

CRO Department Clinical Operations Division

Zip code

103-0027

Address

2-14-1,Nihonbashi,Chuo-ku,Tokyo 103-0027, JAPAN

TEL

03-6386-8809

Homepage URL


Email

food-contact@apoplus.co.jp


Sponsor or person

Institute

APO PLUS STATION CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

NISSIN YORK CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee of Watanabe Hospital

Address

1-5-6, Haneda, Ota-ku, Tokyo, JAPAN

Tel

03-3741-0223

Email

food-contact@apoplus.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団 渡辺病院(Watanabe Hospital)


Other administrative information

Date of disclosure of the study information

2023 Year 08 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 07 Month 31 Day

Date of IRB

2023 Year 08 Month 14 Day

Anticipated trial start date

2023 Year 08 Month 16 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 08 Month 15 Day

Last modified on

2023 Year 10 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059207


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name